Varex Imaging Corporation (NASDAQ: VREX) is a Healthcare company in the Medical - Devices industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | -2.00 | Insider Own | 2.32% | Shs Outstand | 42.10M | Perf Week | 11.14% |
| Market Cap | 520.78M | Forward P/E | 11.25 | EPS next Y | 1.10 | Insider Trans | -0.46% | Shs Float | 41.40M | Perf Month | 15.18% |
| Enterprise Value | 813.78M | PEG | - | EPS next Q | - | Inst Own | - | Short Float | 2.92% | Perf Quarter | 6.55% |
| Income | -83.00M | P/S | 0.61 | EPS this Y | 145.33% | Inst Trans | - | Short Ratio | 2.72 | Perf Half Y | -12.64% |
| Sales | 858.00M | P/B | 1.07 | EPS next Y | 21.25% | ROA | -7.59% | Short Interest | 1.21M | Perf YTD | 6.18% |
| Book/sh | 11.59 | P/C | 5.92 | EPS next 5Y | 28.86% | ROE | -17.61% | 52W High | 14.57 -15.10% | Perf Year | 72.28% |
| Cash/sh | 2.09 | P/FCF | - | EPS past 3/5Y | - | ROIC | -3.41% | 52W Low | 6.90 79.28% | Perf 3Y | -46.33% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | -0.55% 2.74% | Gross Margin | 33.55% | Volatility | 4.64% 4.39% | Perf 5Y | -53.62% |
| Dividend TTM | - | EV/Sales | 0.95 | EPS Y/Y TTM | -70.94% | Oper. Margin | -3.65% | ATR (14) | 0.50 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.43 | Sales Y/Y TTM | 5.80% | Profit Margin | -9.64% | RSI (14) | 75.44 | Recom | 2.33 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.20 | EPS Q/Q | 171.43% | SMA20 | 12.81% | Beta | 0.89 | Target Price | 14.50 |
| Payout | 0.00% | Debt/Eq | 0.83 | Sales Q/Q | 1.41% | SMA50 | 16.41% | Rel Volume | 0.87 | Prev Close | 11.92 |
| Employees | 2,400 | LT Debt/Eq | 0.81 | Earnings | Aug 10 | SMA200 | 6.12% | Avg Volume | 457.07K | Price | 12.37 |
| IPO Date | Jan 23, 2017 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 43.40% 0.87% | Net Debt/EBITDA | -47.69 | Volume | 397,462 | Change | 3.78% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Feb-02-26 | Reiterated | Jefferies | Hold | $17 → $15 |
| May-28-24 | Reiterated | Jefferies | Hold | $17 |
| Feb-05-21 | Upgrade | Oppenheimer | Perform → Outperform | |
| Aug-13-20 | Downgrade | Oppenheimer | Outperform → Perform | |
| May-13-20 | Downgrade | JP Morgan | Overweight → Neutral | |
| Mar-25-20 | Upgrade | JP Morgan | Neutral → Overweight | |
| Feb-12-20 | Downgrade | Jefferies | Buy → Hold | |
| Dec-20-17 | Upgrade | JP Morgan | Underweight → Neutral | |
| Oct-04-17 | Downgrade | JP Morgan | Neutral → Underweight | |
| Aug-08-17 | Upgrade | JP Morgan | Underweight → Neutral |
Varex Imaging Corporation (VREX) specializes in the development and production of X-ray imaging components. Its operations are divided into two primary divisions: Medical and Industrial. Within the Medical segment, Varex provides a comprehensive range of X-ray imaging components. These include essential hardware like X-ray tubes, digital detectors, and high-voltage connectors, alongside sophisticated software solutions for image processing, 3D reconstruction, and computer-aided diagnostics. The segment also supplies critical ancillary devices such as collimators, generators, and automatic exposure control mechanisms. These medical products serve a wide spectrum of applications, from general diagnostic imaging like radiography and fluoroscopy, to specialized areas such as mammography, computed tomography (CT), cardiac procedures, dental imaging, and surgical applications. They are also vital for radiation therapy, oncology, and advanced computer-aided detection systems. The Industrial segment focuses on providing X-ray technology for security and industrial inspection. Its offerings include Linatron X-ray accelerators, X-ray tubes, digital detectors, and high-voltage connectors. These components are crucial for diverse applications such as airport security scanning, cargo screening at border crossings, and nondestructive testing across various industries. Varex distributes its products through multiple channels, including direct sales to end-users, partnerships with imaging system Original Equipment Manufacturers (OEMs), independent service providers, and a network of distributors. With a significant global footprint, the company maintains operations across North America, South America, Europe, Russia, the Middle East, India, Africa, Asia, and Australia. Established in 2016, Varex Imaging Corporation is headquartered in Salt Lake City, Utah.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 10/3/2025 | FY 2024 9/27/2024 | FY 2023 9/29/2023 | FY 2022 9/30/2022 | FY 2021 10/1/2021 | FY 2020 10/2/2020 | FY 2019 9/30/2019 | FY 2018 9/30/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 858 | 845 | 811 | 893 | 859 | 818 | 738 | 781 | 773 | |
| Cost of Goods Sold Incl. D&A | 570 | 554 | 554 | 603 | 576 | 547 | 548 | 524 | 520 | |
| Gross Profit | 289 | 291 | 257 | 290 | 284 | 272 | 190 | 257 | 254 | |
| Selling, General and Administrative Excl. Other | 136 | 133 | 138 | 128 | 118 | 126 | 142 | 128 | 126 | |
| Research and Development | 89 | 91 | 87 | 85 | 77 | 72 | 79 | 78 | 83 | |
| Other Operating Expense | 93 | 94 | 0 | 0 | 0 | -1 | 3 | 0 | 0 | |
| Operating Income | -32 | -28 | 32 | 77 | 88 | 74 | -34 | 8 | 45 | |
| Interest Expense | 42 | 36 | 31 | 29 | 41 | 43 | 31 | 21 | 22 | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -2 | 4 | 4 | -16 | -3 | -2 | -7 | 34 | 3 | |
| Net Income Before Taxes | -75 | -59 | 5 | 31 | 45 | 29 | -73 | 22 | 26 | |
| Income Taxes | 8 | 11 | 52 | -17 | 14 | 11 | -15 | 6 | -3 | |
| Consolidated Net Income | -83 | -70 | -48 | 47 | 30 | 17 | -58 | 16 | 28 | |
| Net Income From Continuing Operations | -83 | -70 | -47 | 48 | 31 | 18 | -57 | 16 | 28 | |
| Net Income | -83 | -70 | -48 | 47 | 30 | 17 | -58 | 16 | 28 | |
| EPS (Recurring) | -1.99 | -1.70 | -1.17 | 1.20 | 0.76 | 0.44 | -1.49 | 0.41 | 0.73 | |
| EPS (Basic, Before Extraordinaries) | -1.99 | -1.70 | -1.17 | 1.20 | 0.76 | 0.44 | -1.49 | 0.41 | 0.73 | |
| EPS (Diluted) | -2.00 | -1.70 | -1.17 | 0.96 | 0.73 | 0.43 | -1.49 | 0.40 | 0.72 | |
| EBITDA | -5 | 4 | 63 | 95 | 115 | 105 | -9 | 84 | 90 | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | 19.57 | 28.96 | 66.47 | — | 71.35 | 39.81 | |
| Price To Sales Ratio | 0.61 | 0.58 | 0.60 | 0.84 | 0.98 | 1.36 | 0.65 | 1.39 | 1.41 | |
| Gross Margin | 33.68 | 34.44 | 31.69 | 32.47 | 33.06 | 33.25 | 25.75 | 32.91 | 32.86 | |
| Operating Margin | -3.73 | -3.31 | 3.95 | 8.62 | 10.24 | 9.05 | -4.61 | 1.02 | 5.82 | |
| Net Margin | -9.67 | -8.28 | -5.92 | 5.26 | 3.49 | 2.08 | -7.86 | 2.05 | 3.62 | |
| Shares Outstanding | 42 | 41 | 41 | 40 | 40 | 39 | 39 | 38 | 38 | |
| Market Capitalization | 520 | 490 | 489 | 752 | 846 | 1,115 | 482 | 1,085 | 1,089 | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Kunkel Jay K. | Director | Mar 20 '26 | Sale | 11.14 | 4,510 | 50,241 | 23,450 | Mar 23 |
| Kunkel Jay K. | Director | Feb 09 '26 | Option Exercise | 0.00 | 8,483 | 0 | 27,960 | Feb 10 |
| Bardwell Kathleen | Director | Feb 09 '26 | Option Exercise | 0.00 | 8,483 | 0 | 12,102 | Feb 09 |
| Chertoff Jocelyn D | Director | Feb 09 '26 | Option Exercise | 0.00 | 8,483 | 0 | 42,194 | Feb 09 |
| Rosebrough Walter M Jr | Director | Feb 09 '26 | Option Exercise | 0.00 | 10,339 | 0 | 52,654 | Feb 09 |
| GUERTIN TIMOTHY E | Director | Feb 09 '26 | Option Exercise | 0.00 | 8,483 | 0 | 26,777 | Feb 09 |
| TSINGOS CHRISTINE A | Director | Feb 09 '26 | Option Exercise | 0.00 | 8,483 | 0 | 42,655 | Feb 09 |
| Jonaitis Mark S. | SVP and GM, X-Ray Sources | Dec 10 '25 | Option Exercise | 0.00 | 12,599 | 0 | 82,867 | Dec 12 |
| Hartmann Andrew | SVP and GM, Detectors | Dec 10 '25 | Option Exercise | 0.00 | 12,599 | 0 | 39,818 | Dec 12 |
| SANYAL SUNNY | President and CEO | Dec 10 '25 | Option Exercise | 0.00 | 74,265 | 0 | 264,458 | Dec 12 |
| Aranki Karen L | Chief Human Resources Officer | Dec 10 '25 | Option Exercise | 0.00 | 6,665 | 0 | 6,842 | Dec 12 |
| Maheshwari Shubham | Chief Financial Officer | Dec 10 '25 | Option Exercise | 0.00 | 21,029 | 0 | 112,118 | Dec 12 |
| Aranki Karen L | Chief Human Resources Officer | Sep 19 '25 | Sale | 12.34 | 3,174 | 39,167 | 177 | Sep 22 |
| Kunkel Jay K. | Director | Aug 14 '25 | Sale | 10.49 | 3,000 | 31,470 | 19,477 | Aug 15 |
| Kunkel Jay K. | Director | Jun 18 '25 | Sale | 7.77 | 2,575 | 20,008 | 22,477 | Jun 20 |